Clinical trialNCT02282020CompletedPhase 3Interventional

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

SponsorAstraZenecaEnrollment266Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Richard T Penson, Associate Prof. of Medicine
Harvard Medical School (HMS and HSDM)
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

94 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Berazategui, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
La Plata, Argentina
Research Site
San Miguel de Tucumán, Argentina

Belgium

Research Site
Ghent, Belgium
Research Site
Leuven, Belgium

Brazil

Research Site
Ijuí, Brazil
Research Site
Passo Fundo, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Canada

Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada

Czechia

Research Site
Hradec Králové, Czechia
Research Site
Ostrava-Poruba, Czechia
Research Site
Prague, Czechia
Research Site
Zlín, Czechia

Hungary

Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Győr, Hungary
Research Site
Miskolc, Hungary

Israel

Research Site
Afula, Israel
Research Site
Haifa, Israel
Research Site
Holon, Israel
Research Site
Jerusalem, Israel
Research Site
Jerusalem, Israel
Research Site
Petah Tikva, Israel
Research Site
Ramat Gan, Israel
Research Site
Rehovot, Israel
Research Site
Tel Aviv, Israel
Research Site
Tel Litwinsky, Israel
Research Site
Ẕerifin, Israel

54 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Feb 2015
Primary completion: 10 Oct 2018
Completion: 19 Jul 2022
Last update posted: 26 Jul 2022
Registered enrollment: 266
Registry id: NCT02282020

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.